Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bao Pharma Raises $100 Million in Series B Round for Protein/Antibody Drugs

publication date: Aug 26, 2022

Shanghai Bao Pharmaceuticals closed a Series B round with over $100 million to support development of its recombinant protein and antibody drug candidates, including commercialization. Bao Pharma will also advance its pre-clinical projects into clinical trials. The company is building a 75,000 square meter facility in Laodian Industrial Park, located in Shanghai’s Baoshin District, which will house its R&D operations and manufacturing facilities for recombinant protein drugs and injected drugs. The round was led by Oriental Fortune Capital and included Haitong Innovation and Sun Rock Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital